Piramal Pharma to Invest $80M to Expand Lexington Facility

Piramal Pharma Solutions (PPS), a part of Piramal Pharma Ltd, has announced an $80 million investment plan to expand its Lexington, Kentucky facility. 

The company stated that this site specialises in sterile compounding, liquid filling, and lyophilisation for sterile injectable drug products, playing a crucial role in the company’s integrated antibody-drug conjugate (ADC) development and manufacturing program, ADCelerate™. 

The expansion aims to enhance the site’s capacity and technological capabilities, allowing Piramal Pharma to better meet the demands of the rapidly growing injectables market. Funded through a mix of bank loans and internal accruals, the investment will solidify the company’s position as a key player in biologic manufacturing, leveraging its scientific expertise and experience in managing complex technical projects.

The planned expansion will add 24,000 square feet of new manufacturing space, including a new laboratory and advanced equipment to streamline and scale client projects. Major upgrades include the installation of a new filling line, two commercial-scale lyophilisers, a capping machine, and an external vial washer. Currently, the Lexington facility can manufacture 104 product batches annually when operating at peak capacity. However, by the completion of the expansion in Q1 2027, this capacity is expected to more than double, reaching over 240 batches per year.

Nandini Piramal, Chairperson of Piramal Pharma Ltd, emphasised the strategic importance of this expansion, noting that it will enable the Lexington site to fill a critical gap in commercial manufacturing and position the company as a key player in the rapidly expanding injectables market. 

The injectable drug market, which is projected to exceed $20 billion by 2028, has grown substantially due to advancements in research, development, and scientific innovation. As the market continues to expand, Piramal Pharma’s enhanced manufacturing capabilities will be crucial in addressing the rising demand for advanced therapies.

Additionally, the expansion will have a positive impact on the local economy by creating over 40 full-time jobs, fostering a diverse and vibrant workforce. Several clients have already committed to commercialising their products at the Lexington site, marking a significant milestone for Piramal Pharma in delivering innovative solutions at scale. This investment not only accelerates Piramal Pharma’s growth trajectory but also strengthens its ability to provide science-based, white-glove service to customers in the global biologics and injectables market.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.